GBS GLUCOSE BIOSENSOR SYS

GBS Inc. to Present Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Update on August 31

GBS Inc. to Present Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Update on August 31

Company to Host Conference Call & Webcast at 4:30 p.m. ET

NEW YORK, Aug. 29, 2022 (GLOBE NEWSWIRE) -- (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced that it will release its financial results for the fourth quarter and full year ended June 30, 2022, shortly after the NASDAQ market close on Wednesday, August 31. Management will then host a conference call and webcast at 4:30 p.m. ET.

Title:GBS Inc. Fourth Quarter and Full Year 2022 Financial Results

Conference Call & Webcast
Date:Wednesday, August 31, 2022
Time:4:30 p.m. ET
Conference Call Details:Toll-Free: 877-407-3982

International: 201-493-6780

Conference ID: 13731215
 
The conference call will be webcast live from the Company’s website and will be available via the following links:

 
Webcast:



  
The webcast should be accessed 15 minutes prior to the conference call start time.

A replay of the webcast will be available following the conclusion of the live broadcast and will be accessible on the Company’s website.

About GBS Inc.:

GBS Inc. is a life sciences company developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. With the world-first Biosensor Platform, GBS Inc. is developing and launching diagnostic tests urgently needed to help people living with diabetes. For more information, please visit .        

Company Contact:

Alex Arzeno – Vice President of IR & Communications

GBS, Inc.

Investor Contact:

Tim McCarthy – Managing Director

LifeSci Advisors, LLC



EN
29/08/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on GLUCOSE BIOSENSOR SYS

 PRESS RELEASE

Intelligent Bio Solutions Achieves Record Monthly Sales of 12,500+ Uni...

Intelligent Bio Solutions Achieves Record Monthly Sales of 12,500+ Units of Higher-Margin Cartridges in July Company reports all-time-high monthly cartridge sales for July with 60% year-on-year growth NEW YORK, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its highest-ever monthly cartridge sales for July 2025, with a record 519 boxes shipped, representing over 12,500 cartridges and a 60% increase year-on-year. Cartridg...

 PRESS RELEASE

Intelligent Bio Solutions Reports Fiscal 2025 Fourth Quarter and Full ...

Intelligent Bio Solutions Reports Fiscal 2025 Fourth Quarter and Full Year Results, Highlighting Progress on Planned U.S. Market Expansion, Revenue Growth and Increased Operational Efficiencies Company advanced efforts to secure U.S. FDA 510(k) clearance to advance on path towards planned U.S. market expansion beyond Forensic Use Only settings Fourth quarter sequential and year-on-year revenue growth of 16%, supported by increased demand for drug testing cartridges NEW YORK, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medi...

 PRESS RELEASE

Intelligent Bio Solutions to Participate in the Sidoti Micro-Cap Virtu...

Intelligent Bio Solutions to Participate in the Sidoti Micro-Cap Virtual Conference on August 20-21, 2025 NEW YORK, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing and screening solutions, today announced that its management team will participate in the Sidoti Micro-Cap Virtual Conference being held on August 20-21, 2025. Presentation DetailsDate: Thursday, August 21, 2025Time: 9:15 a.m. Eastern TimeRegistration/Webcast Link: For more information a...

 PRESS RELEASE

Intelligent Bio Solutions Announces Preliminary Fiscal Fourth Quarter ...

Intelligent Bio Solutions Announces Preliminary Fiscal Fourth Quarter Revenue with Double-Digit Sequential and Year-Over-Year Growth and Strong Operational Momentum Company anticipates fiscal fourth quarter sequential and year-on-year revenue growth of approximately 16% Company advanced efforts to secure U.S. FDA 510(k) clearance for planned U.S. market entry and strengthened global readiness through system upgrades and localization NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering...

 PRESS RELEASE

Intelligent Bio Solutions Secures Major Drug Testing Tender with Leadi...

Intelligent Bio Solutions Secures Major Drug Testing Tender with Leading London Transport Operator NEW YORK, July 30, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced it has secured a major contract with one of London's largest public transport operators, spanning 14 operational sites in greater London and employing over 4,400 staff. INBS's Intelligent Fingerprinting Drug Screening System will be deployed across a multi-garage bus ne...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch